Understanding how inflammatory signals affect the growth of acute myeloid leukemia cells
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML
This study is looking at how certain proteins in the body, called inflammatory cytokines, affect the growth of acute myeloid leukemia (AML) cells, with the goal of finding new ways to treat AML that can kill cancer cells without harming healthy ones.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10796870 on NIH RePORTER |
What this research studies
This research investigates the role of inflammatory cytokines, particularly interleukin-1β, in the progression of acute myeloid leukemia (AML). By examining how these cytokines influence the growth of AML cells and impede normal cell function, the researchers aim to identify new drug targets that could selectively eliminate malignant cells. The study focuses on understanding the molecular mechanisms behind these interactions, which could lead to more effective treatments for AML patients. If successful, this research could provide a new therapeutic approach that spares healthy cells while targeting cancerous ones.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those whose disease is influenced by inflammatory cytokines.
Not a fit: Patients with acute myeloid leukemia who do not have elevated levels of inflammatory cytokines or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, improving survival rates and reducing the side effects of current therapies.
How similar studies have performed: Other research has shown promising results in targeting inflammatory pathways in cancer treatment, suggesting that this approach could be effective for AML as well.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Agarwal, Anupriya — Oregon Health & Science University
- Study coordinator: Agarwal, Anupriya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.